Chemotherapy eliminates most cancer cells except cancer stem cells. Chloroquine is a potential agent to target cancer stem cells. In this phase II trial for patients with breast cancer who were refractory to anthracycline-based chemotherapy, we combined chloroquine with taxane or taxane-like chemotherapy. The overall response rate of the combination was 45%, higher than the expected overall response rate of 30% with chemotherapy alone.
- Cancer stem cells
- Triple negative breast cancer
ASJC Scopus subject areas
- Cancer Research